WEDNESDAY 21st SEPTEMBER 2016 COMMENCING 9.30 AM
AT THE ANGEL HOTEL, ABERGAVENNY, NP7 5EN

AGENDA

1. Welcome and introduction
2. Apologies
3. Declarations of interest
4. Minutes of previous meeting

To protect commercial confidentiality the following appraisal will be held in private

5. Appraisal 1: Full Submission WPAS
   Golimumab (Simponi®) for the treatment of adults with severe, active non radiographic axial spondyloarthritus with objective signs of inflammation as indicated by elevated C reactive protein and/or magnetic resonance imaging evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs

The meeting will open to the public at approximately 10.30 am

6. Chairman’s report (verbal update)

7. Appraisal 2: Full Submission
   Green tea leaf extract (Catephen®) for the cutaneous treatment of external genital and perianal warts (condylomataacuminata) in immunocompetent patients from the age of 18 years

8. Appraisal 3: Full Submission
   Brivaracetam (Briviact®) adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy

9. Feedback from AWPAG Meeting 22nd June 2016

10. Prescribing of Low Molecular Weight Heparin in Wales
11. Prescribing of Amiodarone for Atrial Fibrillation and Atrial Flutter in Wales 7/AWMSG/0916

12. Safeguarding Users of Opioid Patches by Standardising Patient/Caregiver Counselling 8/AWMSG/0916

13. Appraisal 4: Limited Submission
Rilpivirine (Edurant®) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive patients from 12 years old to < 18 years old with a viral load ≤ 100,000 HIV-1 RNA copies/ml 9/AWMSG/0916 Appendices

14. Appraisal 5: Limited Submissions
Emtricitabine/tenofovir alafenamide (Descovy®) in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1) 10/AWMSG/0916 Appendices

15. Guidance for partnership working between NHS organisations, primary care contractors, the pharmaceutical industry and the allied commercial sector in Wales – document update 11/AWMSG/0916

16. All Wales NOAC Alert Card 12/AWMSG/0916

17. Therapeutic Priorities and Clinical Effectiveness Prescribing Programme Summary 2016–2017 13/AWMSG/0916

18. NPI 2015-2016 Annual Primary Care Prescribing Report 14/AWMSG/0916

Date of next meeting: 12th October 2016 in Cardiff